Characterization of vitamin D receptor ligands with cell-specific and dissociated activity

Molecular Endocrinology

Volumn 20, Issue 12, 2006, Pages 3093-3104

  Castillo, Ana Isabel ^a   Sánchez Martínez, Ruth ^a   Jiménez Lara, Ana María ^a   Steinmeyer, Andreas ^b   Zügel, Ulrich ^b   Aranda, Ana ^a  

^a CSIC   (Spain)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,24 TRIHYDROXY 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 25 CARBOXYLIC ACID 1,1 DIMETHYL ESTER; 1,3,24 TRIHYDROXY 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 25 CARBOXYLIC ACID BUTYL ESTER; 20 METHYL 9,10 SECOCHOLESTA 5,7,10(19) TRIENE 1,3,25 TRIOL; 20 METHYL 9,10 SECOCHOLESTA 5,7,10(19),23 TETRAENE 1,3,25 TRIOL; 20 METHYLCALCITRIOL; 25 (1 METHYLTHIAZOLE 2 YL) 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 1,3,24 TRIOL; 25 (1 OXOHEXYL) 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 1,3,24 TRIOL; 9,10 SECO 5,7,10(19) CHOLESTATRIENE 3,25 DIOL; COLLAGENASE; PROTEIN P160; RETINOIC ACID RECEPTOR BETA; TRYPSIN; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ZK 136607; ZK 157202; ZK 168289; ZK 168492; ZK 191732;

ARTICLE; CELL ACTIVITY; CELL SPECIFICITY; CONTROLLED STUDY; DISSOCIATION; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSACTIVATION;

BIOLOGICAL ASSAY; CALCITRIOL; CELLS, CULTURED; COLLAGENASES; GENES, REPORTER; HUMANS; LIGANDS; PROMOTER REGIONS (GENETICS); PROTEIN CONFORMATION; RECEPTORS, CALCITRIOL; TRANS-ACTIVATION (GENETICS); VITAMIN D RESPONSE ELEMENT;

EID: 33751539419     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2006-0215     Document Type: Article

References (43)

1. Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304
2. Gronemeyer H, Gustafsson JA, Laudet V 2004 Principles for modulation of the nuclear receptor superfamily. Nat Rev 3:950-964
3. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
4. Perissi V, Rosenfeld MG 2005 Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6:542-554
5. Kitagawa H, Fujiki R, Yoshimura K, Mezaki Y, Uematsu Y, Matsui D, Ogawa S, Unno K, Okubo M, Tokita A, Nakagawa T, Ito T, Ishimi Y, Nagasawa H, Matsumoto T, Yanagisawa J, Kato S 2003 The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 113:905-917
6. Rachez C, Freedman LP 2001 Mediator complexes and transcription. Curr Opin Cell Biol 13:274-280
7. Malik S, Roeder RG 2005 Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci 3:256-263
8. Garcia-Villalba P, Jimenez-Lara AM, Aranda A 1996 Vitamin D interferes with transactivation of the growth hormone gene by thyroid hormone and retinoic acid. Mol Cell Biol 16:318-327
9. Jimenez-Lara AM, Aranda A 1999 Vitamin D represses retinoic acid-dependent transactivation of the retinoic acid receptor-β2 promoter: the AF-2 domain of the vitamin D receptor is required for transrepression. Endocrinology 140:2898-2907
10. Jimenez-Lara AM, Aranda A 1999 The vitamin D receptor binds in a transcriptionally inactive form and without a defined polarity on a retinoic acid response element. FASEB J 13:1073-1081
11. Fujiki R, Kim MS, Sasaki Y, Yoshimura K, Kitagawa H, Kato S 2005 Ligand-induced transrepression by VDR through association of WSTF with acetylated histones. EMBO J 24:3881-3894
12. Carmeliet G, Van Cromphaut S, Daci E, Maes C, Bouillon R 2003 Disorders of calcium homeostasis. Best Pract Res Clin Endocrinol Metab 17:529-546
13. DeLuca HF 2004 Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689S-1696S
14. Nagpal S, Na S, Rathnachalam R 2005 Non-calcemic actions of vitamin D receptor ligands. Endocr Rev 26:662-687
15. 3. Chem Biol 6:265-275
16. Verstuyf A, Verlinden L, van Etten E, Shi L, Wu Y, D'Halleweyn C, Van Haver D, Zhu GD, Chen YJ, Zhou X, Haussler MR, De Clercq P, Vandewalle M, Van Baelen H, Mathieu C, Bouillon R 2000 Biological activity of CD-ring modified 1α,25-dihydroxyvitamin D analogs: C-ring and five-membered D-ring analogues. J Bone Miner Res 15:237-252
17. 3. J Cell Biochem 88:267-273
18. 3 (Ro-26-9228). Mol Endocrinol 18:874-887
19. Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S 2006 Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116:892-904
20. 3 receptor permits sensitive interaction with agonist. Mol Pharmacol 57:1206-1217
21. 3 receptor. Mol Pharmacol 58:1067-1074
22. 3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol Endocrinol 14:1788-1796
23. Shankar VN, Byford V, Prosser DE, Schroeder NJ, Makin HL, Wiesinger H, Neef G, Steinmeyer A, Jones G 2001 Metabolism of a 20-methyl substituted series of vitamin D analogs by cultured human cells: apparent reduction of 23-hydroxylation of the side chain by the 20-methyl group. Biochem Pharmacol 61:893-902
24. Gaschott G, Werz O, Steinmeyer A, Steinhilber D, Stein J 2001 Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 288:690-696
25. Castillo AI, Jimenez-lara A M, Tolon RM, Aranda A 1999 Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of the coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1). Mol Endocrinol 13:1141-1154
26. Tolón RM, Castillo AI, Jiménez-Lara AM, Aranda A 2000 Association with Ets causes a ligand-AF2-independent activation of nuclear receptors. Mol Cell Biol 20:8793-8802
27. Pike AC, Brzozowski AM, Walton J Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153
28. Carlberg C 2004 Ligand-mediated conformational changes of the VDR are required for gene transactivation. J Steroid Biochem Mol Biol 90:227-232
29. Norman AW, Mizwicki MT, Norman DPG 2004 Steroid-hormone rapid actions, membrane receptors and conformational ensemble model. Nat Rev Drug Discovery 3:27-41
30. Mizwicki MT, Bishop JE, Norman AW 2005 Application of the vitamin D sterol-vitamin D receptor (VDR) conformational ensemble model. Steroids 70:464-471
31. Tocchini-Valentini G, Rochel N, Wurtz JM, Moras D 2004 Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogs calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J Med Chem 47:1956-1961
32. Tocchini-Valentini G, Rochel N, Wurtz JM, Mitschler A, Moras D 2001 Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc Natl Acad Sci USA 98:5491-5496
33. 3-26,23-lactone depends on the primary structure of the carboxyl-terminal region of the vitamin D receptor. Mol Endocrinol 19:1147-1157
34. Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J, Kato S 1999 Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19:1049-1055
35. Shah S, Islam MN, Herrel R, Rizvi I, Dakshanamurthy S, Rao M, Zinder G, Valrance M, Aranda A, Moras D, Norman A, Welsh JE, Byers SW 2006 The molecular basis of vitamin D receptor and b-catenin cross regulation. Mol Cell 21:799-809
36. Jiménez-Lara AM, Aranda A 1999 Lysine-246 of the vitamin D receptor is crucial for ligand-dependent interaction with coactivators and transcriptional activity. J Biol Chem 274:3503-13510
37. Vayssiere B M, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-rigon M 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255
38. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, Pfahl M 1994 A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111
39. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, Reczek P, Chambon P, Gronemeyer H 1995 RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J 14:1187-1197
40. Li, Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X 1999 Identification of a novel class of retinoic acid receptor β-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem 274:15360-15366
41. Benkoussa M, Brand C, Delmotte MH, Formstecher P, Lefebvre P 2002 Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter. Mol Cell Biol 22:4522-4534
42. Germain P, Kammerer S, Perez E, Peluso-Iltis C, Tortolani D, Zusi FC, Starrett J, Lapointe P, Daris JP, Marinier A, de Lera AR, Rochel N, Gronemeyer H 2004 Rational design of RAR-selective ligands revealed by RARβ crystal stucture. EMBO Rep 5:877-882
43. 3 analog with reduced hypercalcemic activity. J Invest Dermatol 119:1434-1442